Leerink Partners Assumes Connect Biopharma Hldgs at Outperform, Announces Price Target of $4
Leerink Partners analyst Will Soghikian assumes Connect Biopharma Hldgs (NASDAQ:CNTB) with a Outperform rating and announces Price Target of $4.
Stocks · News reference
Nasdaq Gains Over 100 Points; Jabil Posts Upbeat Earnings
U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold also climbed.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on Connect Biopharma Hldgs, Maintains $7 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and maintains $7 price target.
Crude Oil Rises Over 1%; Conagra Brands Earnings Top Views
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Connect Biopharma Reports Significant Drop In Treatment Failure With New COPD Therapy
Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COPD treatment failure and high safety.
Why Super Micro Computer Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Super Micro lifts Q1 revenue outlook on AI demand, sending shares up 13%; Robin Energy led premarket gainers, while Alpha Teknova fell after $40M offering.
DarkIris shares are trading lower after the company announced a 1-for-50 reverse stock split, effective October 22.